Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.27455 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An additional gastrojejunostomy may reduce the incidence of moderate and severe delayed gastric emptying after distal segmental duodenectomy for gastrointestinal stromal tumors.
World J Surg Oncol
November 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Sarcoma Center, Peking University Cancer Hospital & Institute, Beijing, China.
Article Synopsis
- * Out of 50 patients, those who had bypass surgery (with gastrojejunostomy) experienced significantly less grade B-C DGE compared to those who didn't, suggesting the bypass may be beneficial.
- * Although the bypass group showed a trend towards shorter hospital stays, the difference wasn’t statistically significant, indicating further research is needed on the overall benefits of the gastrojejunostomy procedure.
Letter to the Editor regarding 'A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse' by JY Blay et al.
Ann Oncol
September 2024
Department of Traditional Chinese Medicine, Community Health Service Center of Guali Town of Xiaoshan, Hangzhou, China. Electronic address:
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network.
Clin Lymphoma Myeloma Leuk
September 2024
Department of Hematology, Università Federico II, Napoli, Italy.
Article Synopsis
- In the past decade, targeted kidney inhibitors (TKIs) have significantly improved the survival rates of chronic myeloid leukemia (CML) patients, particularly those achieving deep and sustained molecular response (DMR), allowing some to consider stopping treatment.
- A study analyzed responses from 1,777 CML patients in Italy, focusing on the impact of different TKIs (imatinib, dasatinib, nilotinib) and timing of responses (3, 6, and 12 months).
- Results showed that patients achieving certain molecular response benchmarks at 3 months were more likely to achieve DMR later, with significant differences in outcomes based on the specific TKI used.
Unprecedented Megakaryocytic Blast Phase Transformation in Chronic Myeloid Leukemia After 16 Years of Tyrosine Kinase Inhibitor Therapy.
Cureus
August 2024
Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, JPN.
We report the case of a 51-year-old Japanese man with chronic myeloid leukemia (CML) initially diagnosed in the chronic phase. For 16 years, the patient maintained chronic phase (CP) under treatment with first- and second-generation tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib, and bosutinib, none of which resulted in ABL1 mutations. However, despite long-term disease stability, the patient experienced an abrupt progression to the megakaryocytic blast phase (MBP), a rare and aggressive form of CML.
View Article and Find Full Text PDFReply to the manuscript 'A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse' by J.-Y. Blay et al.
Ann Oncol
December 2024
Oncology Unit, Casa di Cura Igea, Milano, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!